Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Seizure, Moderate to late preterm birth, Gastroesophageal reflux, and Dilated third ventricle and others; and very common findings: Overactive reflexes (hyperreflexia). 58 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 17 | Exaggerated startle response, Encephalopathy, Seizure |
Muscles | 4 | Shrinkage of the caudate nucleus (brain) (caudate atrophy), Low muscle tone (hypotonia), Global brain atrophy |
Arms and legs | 3 | Large hands, Limb hypertonia, Long foot |
Head and neck | 3 | Progressive microcephaly, Microcephaly, Primary microcephaly |
Eyes | 3 | Optic nerve hypoplasia, Cerebral visual impairment, Blindness |
Digestive system | 2 | Gastroesophageal reflux, Feeding difficulties |
Growth and development | 2 | Failure to thrive, Intrauterine growth retardation |
Lungs and breathing | 2 | Difficulty breathing (respiratory insufficiency), Sleep apnea |
Pregnancy and birth | 1 | Decreased fetal movement |
Asparagine synthetase deficiency (ASD) mainly presents as a triad of congenital microcephaly, severe developmental delay, and axial hypotonia followed by spastic quadriplegia. Low cerebrospinal fluid (CSF) asparagine concentration can help differentiate this disorder from others with similar clinical findings [, , , , ]. Age of onset is soon after birth in most reported individuals (median age of onset: 1 day; range: 1 day to 9 months). Table 2: Asparagine Synthetase Deficiency: Frequency of Select Features
Feature | % of Persons w/Feature | Comment |
|---|---|---|
Developmental delay | 100% | Severe global delay in all persons |
Microcephaly | 100% | Congenital progressive |
ASNS encodes asparagine synthetase (glutamine-hydrolyzing) (561 aa). Highest expression in Brain Cerebellar Hemisphere (121.3 TPM) and Cells Cultured fibroblasts (114.1 TPM).
Congenital microcephaly - severe encephalopathy - progressive cerebral atrophy syndrome is caused by mutations in the ASNS gene on chromosome 7.
The ASNS protein participates in unfolded protein:(Glc)2 (GlcNAc)2 (Man)9 (Asn)1, unfolded protein:(Glc)3 (GlcNAc)2 (Man)9 (Asn)1, and unfolded protein:(Glc)1 (GlcNAc)2 (Man)9 (Asn)1 pathways.
ASNS is classified as a druggable target (Clinically Actionable and Enzyme categories) with score 11.6.
No clinically relevant genotype-phenotype correlations have been reported.
Source: GeneReviews — "Asparagine Synthetase Deficiency"
No consensus clinical diagnostic criteria for asparagine synthetase deficiency (ASD) have been published.
ASD should be suspected in individuals with the following clinical, laboratory, and brain MRI findings and family history.
Clinical findings
Congenital and progressive microcephaly
Severe global developmental delay
Hypotonia followed by spastic quadriplegia, seizures, jitteriness, and hyperekplexia
Intrauterine growth restriction with subsequent feeding difficulties, failure to gain weight, and short stature
Cortical blindness
Laboratory findings
Source: GeneReviews — "Asparagine Synthetase Deficiency"
The differential diagnosis of asparagine synthetase deficiency (ASD) is wide. The cardinal features of spastic quadriplegia, microcephaly, and low cerebrospinal fluid asparagine concentration may aid clinicians in differentiating ASD from disorders with overlapping phenotypes . Table 3. Asparagine Synthetase Deficiency: Differential Diagnosis
Gene(s)/Genetic Mechanism | Phenotype/Disorder | MOI | Clinical Features of Phenotype/Disorder |
|---|---|---|---|
Overlapping w/ASD | Distinguishing from ASD 100 genes1 | Primary microcephaly (MCPH) | AR(AD)1 |
No spastic quadriplegia ATRCEP152CEP63CPAP (CENPJ)DNA2NINNSMCE2RBBP8TRAIP |
Genetic testing for ASNS is available. Testing is considered confirmatory for diagnosis.
No approved treatments are currently available for congenital microcephaly - severe encephalopathy - progressive cerebral atrophy syndrome. The disease remains an area of unmet medical need.
No clinical practice guidelines for asparagine synthetase deficiency (ASD) have been published. In the absence of published guidelines, the following recommendations are based on the authors' personal experience managing individuals with this disorder.
To establish the extent of disease and needs in an individual diagnosed with ASD, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 4.
Asparagine Synthetase Deficiency: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comments
| Developmental assessment | • To incl motor, adaptive, cognitive, speech-language eval
Eval for early intervention/ special education
| Neurologic eval | • EEG if seizures are a concern
Brain MRI to evaluate extent of disease
Assessment for abnormal tone, spasticity, movement disorder
| Clinical eval for scoliosis | • Consider radiographic scoliosis survey (radiographs of spine) based on clinical suspicion.
Consider referral to orthopedist if scoliosis is present.
Gastrointestinal/
| Assess growth parameters to identify those w/poor weight gain. |
Assess for feeding problems incl difficulty w/sucking, swallowing, GERD. | Referral to feeding therapist if feeding problems identified
Assess for constipation. |
| Ophthalmologic eval | Consider visual evoked potential test.
| Sleep study to assess for apnea as needed |
...
Source: GeneReviews — "Asparagine Synthetase Deficiency"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Asparagine Synthetase Deficiency"
1 trial found
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 6. Asparagine Synthetase Deficiency: Recommended Surveillance
System/Concern | Evaluation | Frequency |
|---|---|---|
Development | Monitor developmental progress educational needs. | At each visit Neurologic |
Vision | Ophthalmologic eval to assess for vision impairment cortical blindness | Annually |
Respiratory | Assess for evidence of aspiration respiratory insufficiency. | At each visit |
Hearing | Audiologic eval | If concern for hearing loss |
Family/Community | Assess family need for social work support (e.g., palliative/respite care, home nursing, other local resources), care coordination, or follow-up genetic counseling if new questions arise (e.g., family planning) | At each visit OT = occupational therapy; PT = physical therapy |
Source: GeneReviews — "Asparagine Synthetase Deficiency"
Phenotype severity distribution: 32 always present features, 1 very common feature, 14 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
1 clinical trial registered. Interventions under study include other interventions. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
7 publications have been identified in PubMed for congenital microcephaly - severe encephalopathy - progressive cerebral atrophy syndrome. Research spans Review / Meta-Analysis (29%), Case Report / Case Series (29%), and Basic Science / Preclinical (29%).
Pearce LA (2026). [PMID: 41676621](https://pubmed.ncbi.nlm.nih.gov/41676621/). *bioRxiv*. [Basic Science / Preclinical]
Rae CD (2025). [PMID: 40506607](https://pubmed.ncbi.nlm.nih.gov/40506607/). *Neurochem Res*. [Review / Meta-Analysis]
Dardas Z (2025). [PMID: 40267907](https://pubmed.ncbi.nlm.nih.gov/40267907/). *Am J Hum Genet*. [Gene Therapy / Novel Therapeutics]
Cheng S (2025). [PMID: 40421135](https://pubmed.ncbi.nlm.nih.gov/40421135/). *Front Neurosci*. [Case Report / Case Series]
Stenton SL (2024). [PMID: 38685113](https://pubmed.ncbi.nlm.nih.gov/38685113/). *Hum Genomics*. [Review / Meta-Analysis]
Jahanpanah M (2024). [PMID: 38546112](https://pubmed.ncbi.nlm.nih.gov/38546112/). *Molecular genetics & genomic medicine*. [Case Report / Case Series]
Zhu Y (2024). [PMID: 38586957](https://pubmed.ncbi.nlm.nih.gov/38586957/). *Circulation*. [Basic Science / Preclinical]
Data assembled from 9 of 12 sources · Last updated Sep 20, 2026, 5:37 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Seizures | 82% | — |
Spasticity | 80% | — |
Jitteriness | 78% | — |
Hyperreflexia | 70% | — |
Axial hypotonia | 55% | — |
Hyperekplexia | 55% | — |
Visual impairment | 40% | Microcephaly. Congenital microcephaly is reported in all individuals, ranging between 26.5 cm and 33.4 cm at birth (1-4 standard deviations [SD] below the mean). Microcephaly is progressive and head circumference may decline to nine SD below the mean by early childhood. |
Source: GeneReviews — "Asparagine Synthetase Deficiency"
Seckel syndrome (OMIM PS210600) |
AR |
Microcephaly; Intrauterine growth restriction; Sloping forehead; Short stature |
Tubulinopathies Overview.) | AD | Cerebellar hypoplasia; Simplified gyral pattern; Spastic quadriplegia | Lissencephaly generalized polymicrogyria |
Normal CSF asparagine concentration 17p13.3 contiguous gene deletion (inclPAFAH1B1 [LIS1] YWHAE) | Miller-Dieker syndrome (OMIM 247200) | AD | Hypotonia; Global DD; Spastic quadriplegia |
Smith-Lemli-Opitz syndrome | AR | Microcephaly; Global DD | Prenatal postnatal growth restriction; Dysmorphic features; Syndactyly of 2nd 3rd toes; Postaxial polydactyly; Congenital heart defect; Hypospadias in males; No spastic quadriplegia; Low total cholesterol w/ 7-dehydrocholesterol BRD4 HDAC8 NIPBL RAD21 SMC1A SMC3 |
Cornelia de Lange syndrome | ADXL | Microcephaly; Growth restriction; DD; Spastic quadriplegia4 | Distinctive facial features; Hirsutism; Upper-limb reduction defects ranging from subtle phalangeal abnormalities to oligodactyly PHGDH PSAT1 PSPH |
Serine deficiency disorders | AR | Microcephaly; Neonatal seizures; DD; Spastic quadriplegia | Low CSF serine glycine concentration; Cataract; Nystagmus 40 genes |
Congenital disorders of N-linked glycosylation and multiple pathways | ARXL | Microcephaly; Neonatal seizures; Poor growth; Hypotonia; DD; Cerebellar hypoplasia | Hepatopathy; Hypoglycemia; Protein-losing enteropathy; Eye abnormalities; Immunologic findings; Skin abnormalities; Skeletal findings; Abnormal TIF; Normal CSF asparagine concentration |
WWOX | Developmental epileptic encephalopathy (OMIM 616211) | AR | Congenital microcephaly; Severe DD; Hypotonia; Spastic quadriplegia; Thin corpus callosum; Delayed myeli... |
Source: GeneReviews — "Asparagine Synthetase Deficiency"